Results 181 to 190 of about 221,867 (307)

Single‐Cell Level Characterization of B Cell Depletion and Repopulation Following Rituximab in Systemic Lupus Erythematosus

open access: yesArthritis &Rheumatology, EarlyView.
Objective Rituximab, a CD20+ B cell depletion therapy, is frequently used to treat systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation.
Haerin Jang   +9 more
wiley   +1 more source

Non-Conventional and Emerging Autoantibodies in Sjögren’s Disease

open access: yesJournal of Inflammation Research
Adrian YS Lee1,2 1Department of Clinical Immunology & Allergy, Westmead Hospital & ICPMR, Sydney, NSW, Australia; 2Centre for Immunology & Allergy Research, Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW ...
Lee AYS
doaj  

Factors associated with interstitial lung disease among patients with idiopathic inflammatory myopathies. [PDF]

open access: yesRheumatology (Oxford)
Wilkerson JC   +8 more
europepmc   +1 more source

Unveiling Endotypes in Systemic Lupus Erythematosus Through Multiomic Analysis: Insights Into Cardiovascular and Renal Complications

open access: yesArthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) shows clinical and molecular heterogeneity, and cardiovascular (CV) complications and lupus nephritis (LN) remain leading causes of morbidity and mortality. This study investigated whether omic profiling can reveal molecular endotypes linked to these outcomes.
Tomás Cerdó   +84 more
wiley   +1 more source

A Rare RIPK3 Variant Enhances Necroptosis and Promotes Inflammation in a Still's Disease‐like Autoinflammatory Syndrome

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives Still's Disease represents a prototypical polygenic systemic autoinflammatory diseases (SAIDs), characterized by recurrent systemic inflammation and dysregulation of innate immunity. Despite extensive clinical characterization, familial clustering Still's disease remains unreported.
Longfang Chen   +23 more
wiley   +1 more source

Interleukin‐2 Deprived State of Regulatory T cells and Their Recovery by Low‐Dose Interleukin‐2 in Patients With Inflammatory Myopathies

open access: yesArthritis &Rheumatology, EarlyView.
Objective Regeneration and expansion of Treg by low‐dose interleukin‐2 (IL‐2) therapy is considered a potential treatment strategy for a wide range of autoimmune diseases. To provide a pathophysiologically‐based rationale for low‐dose IL‐2 therapy, we investigated whether reversible defects in the Treg–IL‐2 axis emerge in inflammatory myopathies ...
Justus Ohmes   +10 more
wiley   +1 more source

Association of G-Protein-Coupled Receptors autoantibodies with vasoregulation in Post-COVID. [PDF]

open access: yesPLoS One
Seibert FS   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy